Banner

IOP-lowering agents evaluated in real-world setting

Article

Pittsburgh-IOP-lowering products evaluated in the "real-world" setting of a clinical practice can provide valuable information for practitioners, according to Evan B. Dreyer, MD, PhD.

Related Videos
Related Content

Novartis finalizes divestment of ‘front of eye’ ophthalmology assets

September 30th 2023

EyePod: Week in Review - September 24, 2023

September 30th 2023

Outlook Therapeutics requests Type A meeting with FDA

September 29th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

BLOG: MicroPulse TLT for patients who struggle with drops

September 29th 2023

Digital healthcare startup eyecbetter kicks off Regulation C crowdfunding campaign on StartEngine

September 28th 2023

Novartis finalizes divestment of ‘front of eye’ ophthalmology assets

September 30th 2023

EyePod: Week in Review - September 24, 2023

September 30th 2023

Outlook Therapeutics requests Type A meeting with FDA

September 29th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

BLOG: MicroPulse TLT for patients who struggle with drops

September 29th 2023

Digital healthcare startup eyecbetter kicks off Regulation C crowdfunding campaign on StartEngine

September 28th 2023

Novartis finalizes divestment of ‘front of eye’ ophthalmology assets

September 30th 2023

EyePod: Week in Review - September 24, 2023

September 30th 2023

Outlook Therapeutics requests Type A meeting with FDA

September 29th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

BLOG: MicroPulse TLT for patients who struggle with drops

September 29th 2023

Digital healthcare startup eyecbetter kicks off Regulation C crowdfunding campaign on StartEngine

September 28th 2023
© 2023 MJH Life Sciences

All rights reserved.